Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer
- PMID: 12820354
Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer
Abstract
Background: Several studies suggest that immunological components play a key role in the development of cervical cancer. Polymorphism in the IL-1 RA gene was associated with various malignant diseases. Data is lacking for cervical cancer.
Materials and methods: In a prospective study we analysed the polymorphism of IL-1RA in 113 women with cervical cancer and 107 with benign diseases. Genomic DNA fragments were amplified by PCR.
Results: The distribution of genotype frequencies was different between the study and control group with respect to allele 2 heterozygotes (24.8% vs. 13.1%; p = 0.04) but not in the frequencies of allele 1/3 and homozygous allele 2. There were no differences between IL-1 RA 1/2 polymorphism and all other alleles in tumour stage, grading, recurrence status and age.
Conclusion: This data supports the role for allele 2 of the gene encoding for IL1-RA as a genetic determinant of cervical cancer.
Similar articles
-
Impact of polymorphism in IL-1RA gene on the risk of cervical cancer.Arch Gynecol Obstet. 2008 Jun;277(6):527-33. doi: 10.1007/s00404-007-0504-4. Arch Gynecol Obstet. 2008. PMID: 18008080
-
Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1205-8. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 14652282
-
Association of interleukin-1Ra gene polymorphism in patients with bladder cancer: case control study from North India.Urology. 2006 May;67(5):1099-104. doi: 10.1016/j.urology.2005.11.032. Urology. 2006. PMID: 16698387
-
A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis.Gynecol Oncol. 2004 Mar;92(3):936-40. doi: 10.1016/j.ygyno.2003.11.039. Gynecol Oncol. 2004. PMID: 14984963
-
[Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients].Zhonghua Yi Xue Za Zhi. 2002 Sep 25;82(18):1237-41. Zhonghua Yi Xue Za Zhi. 2002. PMID: 12425801 Chinese.
Cited by
-
Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.BMC Cancer. 2006 Jul 14;6:188. doi: 10.1186/1471-2407-6-188. BMC Cancer. 2006. PMID: 16842617 Free PMC article.
-
Variants in interleukin family of cytokines genes influence clearance of high risk HPV in HIV-1 coinfected African-American adolescents.Hum Immunol. 2013 Dec;74(12):1696-700. doi: 10.1016/j.humimm.2013.08.010. Epub 2013 Aug 21. Hum Immunol. 2013. PMID: 23973891 Free PMC article.
-
A polymorphism at miRNA-122-binding site in the IL-1α 3'UTR is associated with risk of epithelial ovarian cancer.Fam Cancer. 2014 Dec;13(4):595-601. doi: 10.1007/s10689-014-9739-y. Fam Cancer. 2014. PMID: 25195148
-
Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas.Heliyon. 2023 Mar 28;9(4):e14960. doi: 10.1016/j.heliyon.2023.e14960. eCollection 2023 Apr. Heliyon. 2023. PMID: 37025835 Free PMC article. Review.
-
A functional variant at miRNA-122 binding site in IL-1α 3' UTR predicts risk and HPV-positive tumours of oropharyngeal cancer.Eur J Cancer. 2015 Jul;51(11):1415-23. doi: 10.1016/j.ejca.2015.04.016. Epub 2015 May 14. Eur J Cancer. 2015. PMID: 25981582 Free PMC article.